Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Beijing Biotech
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Essen Biotech
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
University Health Network, Toronto
M.D. Anderson Cancer Center
Hadassah Medical Organization
University Health Network, Toronto
TCR2 Therapeutics
TCR2 Therapeutics
Herlev Hospital
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Centre Hospitalier Universitaire Vaudois
ImmunityBio, Inc.
Peking University
Immatics US, Inc.
Acepodia Biotech, Inc.
M.D. Anderson Cancer Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Gilead Sciences
Leap Therapeutics, Inc.
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
Herlev Hospital
Ludwig Institute for Cancer Research
Fudan University
Fudan University
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Roswell Park Cancer Institute
Shanghai 6th People's Hospital
Mie University
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Abramson Cancer Center at Penn Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Pennsylvania
National Institutes of Health Clinical Center (CC)